Castiglione S, Kennedy K A, Floridi A, Fiskum G
Laboratory for Cell Metabolism and Pharmacokinetics, Regina Elena Institute for Cancer Research, Rome, Italy.
Biochem Pharmacol. 1993 Jul 20;46(2):330-2. doi: 10.1016/0006-2952(93)90423-t.
Lonidamine is an antispermatogenic and anticancer drug that is believed to act by inhibition of energy metabolism. In this study, the effects of Lonidamine on the concentration of intracellular free Ca2+ of several tumor cell lines were assessed because of the important role that cytosolic Ca2+ plays in cell viability and proliferation. The presence of 300 microM Lonidamine resulted in large elevations of cytosolic Ca2+ (> 100 nM) in AS-30D rat ascites hepatoma cells and in cultured EMT6 murine mammary adenocarcinoma cells but had little effect on cultured NCI-H345 human small cell lung cancer cells. The apparent EC50 for Lonidamine was approximately 175 microM. The source of elevated cytosolic Ca2+ was primarily intracellular stores, and the effects of Lonidamine on Ca2+ efflux from these stores did not appear to be due to an ionophoretic action of this compound or to a decline in the level of cellular ATP. These results indicate that the Ca2+ homeostasis of certain lines of tumor cells is specifically altered by Lonidamine at concentrations known to affect cell proliferation.
氯尼达明是一种抗生精和抗癌药物,据信其作用机制是抑制能量代谢。在本研究中,评估了氯尼达明对几种肿瘤细胞系细胞内游离Ca2+浓度的影响,因为胞质Ca2+在细胞活力和增殖中起着重要作用。300微摩尔的氯尼达明使AS-30D大鼠腹水肝癌细胞和培养的EMT6小鼠乳腺腺癌细胞的胞质Ca2+大幅升高(>100纳摩尔),但对培养的NCI-H345人小细胞肺癌细胞影响不大。氯尼达明的表观半数有效浓度(EC50)约为175微摩尔。胞质Ca2+升高的来源主要是细胞内储存,氯尼达明对这些储存中Ca2+外流的影响似乎不是由于该化合物的离子载体作用或细胞ATP水平的下降。这些结果表明,在已知影响细胞增殖的浓度下,氯尼达明会特异性改变某些肿瘤细胞系的Ca2+稳态。